Association between Transfusion Status and Overall Survival in Patients with Myelodysplastic Syndromes: A Systematic Literature Review and Meta-Analysis
- PMID: 27160308
- DOI: 10.1159/000445163
Association between Transfusion Status and Overall Survival in Patients with Myelodysplastic Syndromes: A Systematic Literature Review and Meta-Analysis
Abstract
Introduction: Multiple studies show that transfusion independence (TI) in myelodysplastic syndrome (MDS) has a positive impact on overall survival (OS). To assess this, a systematic review and meta-analysis of the association between TI and OS in patients with MDS was conducted (PROSPERO ID: CRD42014007264).
Methods: Comprehensive searches of 5 key bibliographic databases were conducted and supplemented with additional search techniques. Included were studies that had recruited adults aged >18 years with MDS and had examined the impact of transfusion status on OS.
Results: Fifty-five studies (89 citations) were included. The vast majority reported a statistically significant hazard ratio (HR) for OS in favor of TI patients or in patients who acquired TI after treatment. A random-effects meta-analysis was conducted. Patients classed as TI at baseline showed a 59% decrease in the risk of death compared with transfusion-dependent (TD) patients [HR 0.41; 95% credible interval (CrI) 0.29-0.56], and this effect did not appear to interact significantly with illness severity (interaction coefficient HR 1.38; 95% CrI 0.62-3.41). A meta-analysis of studies where patients acquired TI was not possible, but those studies consistently reported a survival benefit for those who acquired TI.
Conclusion: The findings revealed a 59% pooled reduction in mortality among TI patients when compared with TD patients.
© 2016 S. Karger AG, Basel.
Comment on
-
Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes.Eur J Haematol. 2002 Mar;68(3):180-5. doi: 10.1034/j.1600-0609.2002.01530.x. Eur J Haematol. 2002. PMID: 12068800
-
Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin.Leukemia. 2007 Jul;21(7):1436-41. doi: 10.1038/sj.leu.2404747. Epub 2007 May 17. Leukemia. 2007. PMID: 17507999
-
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.J Clin Oncol. 2007 Aug 10;25(23):3503-10. doi: 10.1200/JCO.2006.08.5696. J Clin Oncol. 2007. PMID: 17687155
-
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome.J Clin Oncol. 2008 Jul 20;26(21):3607-13. doi: 10.1200/JCO.2007.15.4906. Epub 2008 Jun 16. J Clin Oncol. 2008. PMID: 18559873
-
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.BMC Med Res Methodol. 2012 Feb 1;12:9. doi: 10.1186/1471-2288-12-9. BMC Med Res Methodol. 2012. PMID: 22297116 Free PMC article.
-
Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis.Leuk Res. 2014 Mar;38(3):304-9. doi: 10.1016/j.leukres.2013.11.005. Epub 2013 Nov 15. Leuk Res. 2014. PMID: 24333115
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
